Metagenomi, Inc. Logo

Metagenomi, Inc.

Discovering novel gene editing tools from nature for curative genetic medicines.

MGX | NDAQ

Overview

Corporate Details

ISIN(s):
US59102M1045
LEI:
Country:
United States of America
Address:
5959 HORTON STREET, 94608 EMERYVILLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Metagenomi, Inc. is a genetic medicines company that develops potentially curative therapeutics using a proprietary, metagenomics-powered genome editing toolbox. The company leverages artificial intelligence and high-throughput screening to mine natural ecosystems for novel cellular systems, discovering and developing a diverse suite of next-generation gene editing tools. Its comprehensive toolbox includes programmable nucleases, base editors, and RNA- and DNA-mediated integration systems (such as prime editing and CRISPR-associated transposases). Metagenomi's strategy focuses on advancing its wholly-owned pipeline of in vivo gene editing therapies for devastating diseases while also pursuing technology out-licensing for ex vivo cell therapy applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Metagenomi, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Metagenomi, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Metagenomi, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
ARGENX SE Logo
Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.
United States of America ARGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.